Abstracts tagged "Janus kinase (JAK)"

Abstract Number: L14 • 2019 ACR/ARP Annual Meeting
Tofacitinib as Monotherapy Following Methotrexate Withdrawal in Patients with Psoriatic Arthritis Previously Treated with Open-label Tofacitinib + Methotrexate: A Randomized, Placebo-controlled Sub-study of OPAL Balance
Peter Nash¹, Laura Coates ², Philip J. Mease ³, Alan Kivitz ⁴, Dafna Gladman ⁵, Frank Behrens ⁶, James C Wei ⁷, Dona Fleishaker ⁸, Joseph Wu ⁸, Cunshan Wang ⁸, Ana Romero ⁹, Lara Fallon ¹⁰, Ming-Ann Hsu ⁸ and Keith Kanik ⁸, ¹Griffith University, Brisbane, Queensland, Australia, ²University of Oxford, Oxford, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, Washington, ⁴Altoona Center for Clinical Research, Duncansville, ⁵University of Toronto, Toronto, Canada, ⁶CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ⁷Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ⁸Pfizer Inc, Groton, Connecticut, ⁹Pfizer Inc, Barcelona, Spain, ¹⁰Pfizer Inc, Montreal, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Tofacitinib monotherapy has not been previously studied in PsA. This sub-study of…
Abstract Number: 2117 • 2019 ACR/ARP Annual Meeting
Impact of Tapering Targeted Therapies (bDMARDs or Jakinibs) on the Risk of Adverse Events of Special Interest in Patients with Rheumatoid Arthritis or Spondyloarthritis: A Systematic Analysis of the Literature and Meta-analysis
DOROTHEE VINSON¹, LUC MOLLET-BENHAMOU ², Yannick Degboe ³, Thao Pham ⁴, Thomas BARNETCHE ⁵, Arnaud Constantin ⁶ and Adeline Ruyssen-Witrand ⁷, ¹AP-HM CHU Marseille, Marseille, France, ²CHU Toulouse, Toulouse, France, ³University of Glasgow, Glasgow, United Kingdom, ⁴Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ⁵CHU Bordeaux, Toulouse, France, ⁶CHU TOUOUSE, TOULOUSE, France, ⁷Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France
Background/Purpose: A previous meta-analysis1 showed that tapering of bDMARDs does not increase the risk of relapse in rheumatoid arthritis (RA) patients with remission or low…
Abstract Number: 2358 • 2019 ACR/ARP Annual Meeting
Short-term Risk of Major Adverse Cardiovascular Events or Venous Thrombo-embolic Events in Patients with Rheumatoid Arthritis Initiating a Janus Kinase Inhibitor: A Meta-analysis of Randomised Controlled Trials
Margaux MALAURIE¹, Arnaud Constantin ², Yannick Degboé ¹, Adeline Ruyssen-Witrand ³ and Thomas Barnetche ⁴, ¹CHU TOULOUSE, TOULOUSE, France, ²CHU TOUOUSE, TOULOUSE, France, ³Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, ⁴FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France
Background/Purpose: The objective was to investigate the short-term risk of major adverse cardiovascular events (MACEs) or venous thromboembolic events (VTEs) in patients with rheumatoid arhthritis…
Abstract Number: 59 • 2019 ACR/ARP Annual Meeting
Evaluation of Potential Mechanisms Underlying the Safety Observations of Filgotinib in Clinical Studies in RA
Julie Di Paolo¹, Bryan Downie ², Amy Meng ³, Nevena Mollova ³, Yuanjiang Yu ³ and Pei Han ³, ¹Gilead Sciences, Foster City, CA, ²Gilead Sciences, Inc., Foster Citty, CA, ³Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Inhibition of the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway have demonstrated efficacy in immune-mediated diseases and haves been identified as therapeutic…
Abstract Number: 2393 • 2019 ACR/ARP Annual Meeting
Risk of Thromboembolism with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis of Randomized Placebo Controlled Trials
Jawad Bilal¹, Irbaz Bin Riaz ², Maryam Sadiq ³, Muhammad Salick ⁴, Yahya Nomaan ⁵, Nusrum Iqbal ⁶, Sandipan Bhattacharjee ⁷, Lary Prokop ⁸ and C. Kent Kwoh ⁷, ¹University of Arizona College of Medicine, Tucson, AZ, ²Mayo Hospital Rochester, Rochester, MN, ³Nishtar Medical College, University of Health Sciences, Lahore, Albany, NY, ⁴Albany Medical Center, Albany, NY, ⁵Phoenix Children's Hospital, Phoenix, AZ, ⁶St Joseph's Hospital, Tucson AZ, Tucson, AZ, ⁷University of Arizona, Tucson, AZ, ⁸Mayo Clinic, Rochestor, MN
Background/Purpose: Importance The efficacy of Janus kinase (JAK) inhibitors is well established across a range of diseases. However, there is a major concern regarding the potential risk of an increased…
Abstract Number: 390 • 2019 ACR/ARP Annual Meeting
Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Samantha Dill ², Michelle O'Brien ², Minal Jain ³, Shajia Lu ⁴, Wanxia Tsai ⁴, Yinghui Shi ⁵, Laura Vian ⁴, Massimo Gadina ⁴, Michelle Millwood ², April Brundidge ², Lisa G. Rider ⁶ and Robert Colbert ¹, ¹Pediatric Clinical Trials Unit, Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ²Pediatric Clinical Trials Unit (PCTU), Office of the Clinical Director, NIAMS, NIH, Bethesda, MD, ³Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁴Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁵Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁶Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 2403 • 2019 ACR/ARP Annual Meeting
Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Mitsuhiro Rokuda ³, Hiroyuki Izutsu ³, Yuichiro Kaneko ³, Musashi Fukuda ³ and Daisuke Kato ³, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in studies of Japanese, Korean and Taiwanese patients with RA. This analysis of…
Abstract Number: 417 • 2019 ACR/ARP Annual Meeting
Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis
Mart A.F.J. van de Laar¹, Janet Pope ², Yvonne Lee ³, Bruno Fautrel ⁴, Kei Ikeda ⁵, Amanda Quebe ⁶, Xiang Zhang ⁶, Carol Gaich ⁶, Francesco De Leonardis ⁶, Jeffrey Lisse ⁶, Jennifer Workman ⁶, Roy Fleischmann ⁷, Mark Genovese ⁸ and Peter Taylor ⁹, ¹Arthritis Center Twente, Enschede, Netherlands, ²Western University, London, ON, Canada, ³Northwestern University Feinberg School of Medicine, Chicago, ⁴Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁵Chiba University Hospital, Chiba, Japan, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁸Stanford University, Stanford, CA, ⁹University of Oxford, Oxford, United Kingdom
Background/Purpose: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, has shown clinical efficacy and patient-reported pain relief in patients (pts) with RA and…
Abstract Number: 2728 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis
Désirée van der Heijde¹, In-Ho Song ², Aileen Pangan ³, Atul Deodhar ⁴, Filip Van den Bosch ⁵, Walter P. Maksymowych ⁶, Tae-Hwan Kim ⁷, Mitsumasa Kishimoto ⁸, Andrea Everding ⁹, Yunxia Sui ¹⁰, Xin Wang ¹⁰, Alvina D. Chu ¹⁰ and Joachim Sieper ¹¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴Oregon Health & Science University, Portland, OR, ⁵Ghent University Hospital, Ghent, Belgium, ⁶University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ⁹HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ¹⁰AbbVie Inc., Chicago, ¹¹Charité Universitätsmedizin Berlin, Germany, Berlin, Germany
Background/Purpose: Patients (pts) with ankylosing spondylitis (AS) who have an inadequate response/contraindication to NSAIDs have limited treatment options other than biologics. The Janus kinase (JAK)…
Abstract Number: 506 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results
Bernard Combe¹, Alan Kivitz ², Yoshiya Tanaka ³, Désirée van der Heijde ⁴, Franziska Matzkies ⁵, Beatrix Bartok ⁵, Lei Ye ⁵, Ying Guo ⁵, Chantal Tasset ⁶, John Sundy ⁵, Neelufar Mozaffarian ⁵, Robert B.M. Landewé ⁷, Sang-Cheol Bae ⁸, Edward Keystone ⁹ and Peter Nash ¹⁰, ¹CHU Montpellier, Montpellier University, Montpellier, France, ²Altoona Center for Clinical Research, Duncansville, PA, ³University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos NV, Mechelen, Belgium, ⁷Amsterdam University Medical Center, Amsterdam, Netherlands, ⁸Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰University of Queensland, Brisbane, Queensland, Australia
Background/Purpose: Filgotinib (FIL) is an orally administered, potent and selective inhibitor of Janus kinase 1 (JAK1) that has shown good efficacy and was well tolerated…
Abstract Number: 2875 • 2019 ACR/ARP Annual Meeting
Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs
Mark Genovese¹, Kenneth Kalunian ², Jacques-Eric Gottenberg ³, Beatrix Bartok ⁴, YingMeei Tan ⁴, Ying Guo ⁴, Chantal Tasset ⁵, John Sundy ⁴, Kurt de Vlam ⁶, David Walker ⁷ and Tsutomu Takeuchi ⁸, ¹Stanford University, Stanford, CA, ²Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁷Northumbria Healthcare, Northumbria, United Kingdom, ⁸Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Anemia, thrombocytopenia and leukopenia in RA patients treated with non-Janus Kinase 1 (JAK1) selective inhibitors may be due to inhibition of hematopoietic growth factors…
Abstract Number: 507 • 2019 ACR/ARP Annual Meeting
Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Mitsuhiro Rokuda ³, Hiroyuki Izutsu ³, Yuichiro Kaneko ³, Musashi Fukuda ³, Daisuke Kato ³ and Désirée van der Heijde ⁴, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Astellas Pharma, Inc., Tokyo, Japan, ⁴Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Peficitinib (PEF), a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in Phase 3 studies of patients with RA (NCT02305849).1 We report the…
Abstract Number: 2907 • 2019 ACR/ARP Annual Meeting
Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response
Roy Fleischmann¹, Mark Genovese ², Ricardo Blanco ³, Stephen Hall ⁴, Glen Thomson ⁵, Filip Van den Bosch ⁶, Cristiano A. Zerbini ⁷, Jose Jeffrey Enejosa ⁸, Yihan Li ⁹, Ryan DeMasi ⁹ and In-Ho Song ⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University, Stanford, CA, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ⁴Monash University and Emeritus Research, Melbourne, Australia, ⁵CIADS Research, Winnipeg, Canada, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁸AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁹AbbVie Inc., North Chicago, IL
Background/Purpose: The goal of RA treatment is to achieve clinical remission or, at minimum, low disease activity (LDA). Modification of initial csDMARD therapy with the…
Abstract Number: 992 • 2019 ACR/ARP Annual Meeting
Identification of CJ-15314, a Novel Highly Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis
So Young Ki¹, Dongkyu Kim ¹, Juhyun Lee ¹, Byoung Seok Moon ¹ and Shin-Young Ryu ¹, ¹CJ Healthcare, Icheon-si, Republic of Korea
Background/Purpose: Janus kinases (JAKs) play critical roles in mediating various cytokine signaling. First-generation non-selective JAK inhibitors such as tofacitinib and baricitinib are widely used for…
Abstract Number: 1352 • 2019 ACR/ARP Annual Meeting
Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies
Martin Bergman¹, Namita Tundia ², Heidi Camp ², Sebastian Meerwein ³, Casey Schlacher ², Debbie Goldschmidt ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Drexel University College of Medicine, Stockholm, Sweden, ²AbbVie Inc., North Chicago, IL, ³AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁴Analysis Group, Inc., New York, NY, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Treatment with upadacitinib (UPA), a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week 12…

1
2
3
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].